Swiss pharmaceutical company Novartis has observed in a clinical trial the superiority of its Scemblix over the current standard of care for patients diagnosed with Philadelphia chromosome-positive chronic myeloid leukaemia after 48 weeks.
This content was published on
2 minutes
Keystone-SDA
Español
es
Novartis avanza con un fármaco contra la leucemia mieloide
The currently experimental treatment has demonstrated a significant response rate both statistically and clinically, thus meeting the two primary evaluation criteria set for the Asc4first program, assures the Basel group in a press release, without time to detail the extent of these advantages.
Scemblix (asciminib) also has a more favorable safety profile than the cocktail of imatinib, nilotinib, dasatinib and bosutinib (TKIs), generally administered to these patients.
Novartis plans to detail the results obtained at an upcoming medical conference. In the meantime, the laboratory points out that more than 60% of people with Philadelphia chromosome-positive chronic myelogenous leukaemia fail to show a molecular response to TKIs after one year and that the side effects of this type of treatment burden lead a quarter of patients to abandon treatment before five years.
The Asc4first program continues, with a new update planned when data on 96 weeks of treatment is available.
More
More
Three Swiss companies among the 100 most valuable in the world
This content was published on
Three Swiss companies have once again made it into the top 100 most valuable listed companies in the world.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Swiss Politics
Why cars still reign supreme in ‘rail-nation’ Switzerland
Swiss government adopts three-pronged approach to end violence against women
This content was published on
Over the next few years, the federal government intends to take action against gender-based violence in three main areas.
Uri voters clear path for hotel and marina complex in central Switzerland
This content was published on
Voters in canton Uri in central Switzerland have rejected a Green Party initiative aimed at regulating the development of the lakeside site in Isleten.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis withdraws patent claim on leukaemia treatment
This content was published on
The Swiss NGO Public Eye is claiming victory in the European Patent OfficeExternal link battle, but Novartis says the patent in question was only one of several it has in place on the (CAR)-T cell therapy treatment it had developed together with the University of Pennsylvania. Public Eye says the therapy costs CHF370,000 ($376,000), which…
Sandoz CEO: Switzerland could save millions on medicines
This content was published on
Sandoz chief executive Richard Saynor says Switzerland could save millions on medicine if it made greater use of generic medicine.
This content was published on
Pressure groups Public Eye and Médecins du Monde have filed their objection to the European patent office in Munich. They claim that Kymriah was not invented by Novartis because the research behind the drug was carried out by public institutions. The medicament, which is used to treat leukaemia and lymph gland cancer on patients who have…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.